Diagnostic Yield of Cranial and Large Vessel Imaging in GCA Combined cranial and large vessel ultrasound and PET/CT provided excellent accuracy for the diagnosis of giant cell arteritis (GCA). https://t.co/0gBXXLy1db https://t.co/zp12wZIkqL

EULAR Offers Tips on Psoriasis Progression to PsA Clinicians treating patients with psoriasis should be on the lookout for certain signs that joint involvement is likely to develop, according to a new "points to consider" from the EULAR. https://t.co/JP7OjpYtBe https://t.co/HMFkzMGOFO

Bringing pivotal clinical trials to you: announcing RheumNow’s Poster Hall, featuring previously presented, sponsor-generated clinical trial posters designed to educate and inform. https://t.co/2hqKVhtzbv https://t.co/2dTvdU2A9t

Biosimilars Match Biologic Originators in RA A JAMA review shows that biosimilars of adalimumab, infliximab, and etanercept were associated w/clinically equivalent treatment effects compared with their ref biologics for treatment of RA. https://t.co/MqxqpzzpiJ https://t.co/Eh98wBUHlj

Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/lpRhRYg7dd https://t.co/kU2gs3Oljg

Metanalysis of 62 RCTs, 16 LTEs of JAKi, placebo, TNFi, & MTX Rx pts shows that malignancy incidence rate =1.15-1.26/100 Pt-Yrs. Neoplasia risk w/ JAKi = PBO or MTX risk (IRR 0.71 & 0.77); but JAKi CA risk if compared to TNFi (IRR 1.50;1.16 to 1.94) https://t.co/uOgPFlJ2z1 https://t.co/Ynh6SMQdke

#RA pts at increased risk of gastroparesis (GP). From 2012–2014 National Inpatient Sample database; among 1.5 million RA, 1070 hospitalized for GP (OR 1.36; 1.24 to 1.49,P< 0.0001). GP risk incr by aging up to 65 yrs, DM, RA, income 26-75th percentiles https://t.co/2U4vSTtxen https://t.co/ub4z4ntcNk

TNR- Rheumatoid Arthritis - Decisive Therapeutics Replay of this RA pod from RheumNow Live 2023, recorded on March 18, 2023 https://t.co/RyyKQFDrT5 https://t.co/ZHjJRzHJ0Q

RheumNow Eular 2023 Daily Recap Series - Day3 June 2, 2023 RheumNow faculty and reporters provide a daily recap of conference content coverage. https://t.co/4aHy2uJOc6 https://t.co/zOBMX7sgXl

Update on CAR T-Cell Therapy in SLE & Autoimmune Diseases Dr. Peter Nash ( @drpnash ) reporting from EULAR 2023 in Milan, Italy. https://t.co/UNXLD5GVKi https://t.co/q8OAexChBN

Artificial Intelligence in Rheumatology: Now and the Future Drs. Antoni Chan and Thomas Hugle discuss abstract POS0892 from EULAR 2023 in Milan, Italy. https://t.co/rftHTKY6MX @synovialjoints https://t.co/PtlKg4o18s

WATCH: JAKpot or JAKnot Dr. Jack Cush, executive editor of RheumNow, reporting on abstract OP0219 from EULAR 2023 in Milan, Italy. https://t.co/RSJX4hcMRU https://t.co/XYuOrSCxjf